Patents Assigned to Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
  • Publication number: 20230165510
    Abstract: The present invention relates to an apparatus for the treatment of an epilepsy-associated disorder in a living being and to a method for the treatment of an epilepsy-associated disorder in a living being.
    Type: Application
    Filed: January 26, 2023
    Publication date: June 1, 2023
    Applicant: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Jens KLINZING, Hong-Viet Victor NGO
  • Patent number: 11591568
    Abstract: The present invention relates to myeloid-derived suppressor cells (MDSC) and exosomes derived therefrom (MDSC exo) and application thereof.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: February 28, 2023
    Assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Natascha Koestlin, Christian Gille
  • Publication number: 20220280526
    Abstract: The present invention relates to the use of EZH2 inhibitors for the treatment of psoriasis, a pharmaceutical composition for the treatment of psoriasis comprising said EZH2 inhibitors, a method for the preparation of said pharmaceutical composition, a method for the therapeutic treatment of a living being against psoriasis, a method for the screening of active agents against psoriasis, and the use in vitro of a EZH2 inhibitor for the suppression of the cellular I?B? expression.
    Type: Application
    Filed: March 29, 2022
    Publication date: September 8, 2022
    Applicant: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET
    Inventors: Daniela KRAMER, Anne MUELLER, Klaus SCHULZE OSTHOFF
  • Publication number: 20220280511
    Abstract: The present invention relates to the use of CDK4/6 inhibitors for the treatment of psoriasis, a pharmaceutical composition for the treatment of psoriasis comprising said CDK4/6 inhibitors, a method for the preparation of said pharmaceutical composition, a method for the therapeutic treatment of a living being against psoriasis, a method for the screening of active agents against psoriasis, and the use in vitro of a CDK4/6 inhibitor for the suppression of the cellular I?B? expression.
    Type: Application
    Filed: March 29, 2022
    Publication date: September 8, 2022
    Applicant: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET
    Inventors: Daniela KRAMER, Anne MUELLER, Klaus SCHULZE OSTHOFF
  • Publication number: 20220249346
    Abstract: The invention relates to a polyribonucleotide, a cosmetic and pharmaceutical compound that has the polyribonucleotide and a medicinal product that has the polyribonucleotide and the compound.
    Type: Application
    Filed: October 5, 2021
    Publication date: August 11, 2022
    Applicant: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Hans-Peter WENDEL, Timea KELLER, Andrea NOLTE, Meltem AVCI-ADALI, Tobias WALKER
  • Publication number: 20220153816
    Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.
    Type: Application
    Filed: December 2, 2021
    Publication date: May 19, 2022
    Applicant: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Michael Schindler, Marius Codrea, Sven Nahnsen, Herwig Koppensteiner, Gundram JUNG, Martin HOFMANN
  • Patent number: 11332726
    Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: May 17, 2022
    Assignees: EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT, HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH FÜR DAS HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND (HIPS)
    Inventors: Michael Kormann, Lauren Mays Weddle, Claus-Michael Lehr, Brigitta Loretz, Emad Malaeksefat
  • Publication number: 20220098677
    Abstract: The present invention relates to a method for determining in a subject's biological sample the relative proportions of papillary renal cell carcinoma (pRCC), clear cell renal cell carcinoma (ccRCC), and chromophobe renal cell carcinoma (chRCC), an array comprising capture molecules capable of specifically binding to RCC signature genes or coding sequences thereof or products encoded thereby, and the use of RCC signature genes for classifying a subject into a renal cell carcinoma (RCC) risk group and/or for determining in a subject's biological sample the relative proportions of pRCC, ccRCC, and chRCC.
    Type: Application
    Filed: October 7, 2021
    Publication date: March 31, 2022
    Applicants: Robert Bosch Gesellschaft für medizinische Forschung mbH, Eberhard Karls Universität Tuebingen Medizinische Fakultaet, Friedrich-Alexander-Universitaet Erlangen-Nuernberg
    Inventors: Florian Buettner, Elke Schaeffeler, Matthias Schwab, Stefan Winter, Jens Bedke, Arnulf Stenzl, Arndt Hartmann
  • Patent number: 11286500
    Abstract: A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 29, 2022
    Assignee: EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT
    Inventors: Hanns-Joachim Rziha, Ralf Amann
  • Patent number: 11229651
    Abstract: The present invention relates to substances for the prophylaxis and treatment of a neurodegenerative disease which is not based on a protein-folding disorder. It further relates to substances for the stabilization of photoreceptors.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: January 25, 2022
    Assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Marius Ueffing, Blanca Arango-Gonzalez, Ana Griciuc
  • Publication number: 20220016219
    Abstract: The present application relates to a pharmaceutical composition for use in a method of treating diabetes in a human or animal subject in need thereof, to transplantation devices comprising the pharmaceutical composition of the present invention and to methods of treating diabetes using the pharmaceutical composition and transplantation device of the present invention.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 20, 2022
    Applicant: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Shannon Layland, Katja Schenke-Layland, Garry Duffy, Svenja Hinderer, Aline Zbinden
  • Patent number: 11208469
    Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 28, 2021
    Assignee: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET
    Inventors: Michael Schindler, Marius Codrea, Sven Nahnsen, Herwig Koppensteiner, Gundram Jung, Martin Hofmann
  • Patent number: 11058777
    Abstract: The present invention relates to a nucleic acid molecule which encodes a splice variant of the human P2RX7 receptor, and nucleic acid molecules derived therefrom, a recombinant vector containing said nucleic acid molecules, a host containing said recombinant vector, a polypeptide encoded by said nucleic acid molecules, a host cell expressing said polypeptide, a binding molecule binding to said polypeptide, a pharmaceutical composition comprising said binding molecule, a method for the production of the isolated polypeptide, and other methods and uses in connection therewith.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: July 13, 2021
    Assignees: EBERHARD KARLS UNIVERSITÄT TUEBINGEN MEDIZINISCHE FAKULTAET, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
    Inventors: Jens Gesche, Sorin Armeanu-Ebinger, Guido Seitz, Harald Surowy
  • Patent number: 10898454
    Abstract: A composition for the prophylaxis and/or treatment of a developmental disorder which is associated with preterm birth, and a method for the diagnosis and/or determination and/or prediction of the degree of severity of a developmental disorder which is associated with preterm birth.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: January 26, 2021
    Assignee: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET
    Inventors: Wolfgang Bernhard, Axel Franz
  • Patent number: 10759752
    Abstract: The present invention relates to a composition for the modulation of the activity of non-structure proteins and a compound contained therein.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 1, 2020
    Assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Bernhard Hirt, Claus Zeyher, Corinna Gleiser, Lothar Just
  • Patent number: 10616699
    Abstract: In a hearing aid (26) that can be inserted into the ear canal (12) of a patient, comprising an actuator (31) effecting a mechanical stimulation of the tympanic membrane (14), the actuator (31) comprises an inner surface (32) associated with the tympanic membrane (14) and an outer surface (42) associated with the ear canal (12) and is configured as an areal disk actuator, whose deformation stimulates the tympanic membrane (14) by areal deformation. On the actuator (31) at a distance from the outer surface (42) a cover plate (43) is arranged which together with the outer surface (42) delimits a preferably lenticular cavity (48).
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: April 7, 2020
    Assignee: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET GESCHWISTER-SCHOLL-PLATZ
    Inventors: Ernst Dalhoff, Hans-Peter Zenner
  • Publication number: 20190381198
    Abstract: The present invention relates to novel compounds useful for visualizing cell senescence in vitro and in vivo, the preparation of said compounds and their use. In particular, the present invention pertains to novel hexose and particularly galactose derivatives which are useful as senescence tracers in vitro and in vivo.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 19, 2019
    Applicant: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Jonathan Cotton, Anna Kuehn, Andreas Maurer, Bernd Pichler, Klaus Schulze-Osthoff, Kerstin Fuchs, Marcel André Krueger, Lars Zender
  • Publication number: 20190376035
    Abstract: The present invention relates to myeloid-derived suppressor cells (MDSC) and exosomes derived therefrom (MDSC exo) and application thereof.
    Type: Application
    Filed: June 4, 2019
    Publication date: December 12, 2019
    Applicant: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Natascha Koestlin, Christian Gille
  • Publication number: 20190376051
    Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.
    Type: Application
    Filed: April 30, 2019
    Publication date: December 12, 2019
    Applicants: Eberhard Karls Universität Tübingen Medizinische Fakultät, Helmholtz-Zentrum für Infektionsforschung GmbH für das Helmholtz-Institut für Pharmazeutische
    Inventors: Michael KORMANN, Lauren Mays WEDDLE, Claus-Michael LEHR, Brigitta LORETZ, Emad MALAEKSEFAT
  • Patent number: 10416173
    Abstract: The present invention relates to a method for the diagnosis of a disease or a risk for the development of a disease, in particular a disease which is mediated via the alternative pathway of the complement system. It further relates to a novel diagnostic marker and methods for identifying active agents.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: September 17, 2019
    Assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
    Inventors: Sascha Dammeier, Eloed Koertvély, Marius Ueffing